Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

115.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 305
Open 115.50
Bid (Size) 115.49 (19)
Ask (Size) 115.68 (1)
Prev. Close 115.50
Today's Range 115.50 - 115.50
52wk Range 60.03 - 115.71
Shares Outstanding 228,994,568
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
From Horizon Therapeutics plc
Via Business Wire
How Is The Market Feeling About Horizon Therapeutics?
Via Benzinga

Performance

YTD
+1.76%
+1.76%
1 Month
+9.72%
+9.72%
3 Month
+13.92%
+13.92%
6 Month
+7.14%
+7.14%
1 Year
+84.74%
+84.74%

More News

Read More
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Via Benzinga
$1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
3 Growth Stocks to Buy in September
Via MarketBeat
Topics Economy
Exposures Economy
This Is What Whales Are Betting On Horizon Therapeutics
Via Benzinga
Peering Into Horizon Therapeutics's Recent Short Interest
Via Benzinga
P/E Ratio Insights for Horizon Therapeutics
Via Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
From Horizon Therapeutics plc
Via Business Wire
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
Via Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
Via Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
Via Investor's Business Daily
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
From Horizon Therapeutics plc and Amgen
Via Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy
Exposures Interest Rates
Is This the Green Light Biotech Stocks Have Been Waiting For?
Via The Motley Fool
Nasdaq, S&P 500 Futures Flatline Ahead Of JOLTS, House Price Data; Why This Analyst Recommends 'Buying Weakness Than Selling Rallies'
Via Benzinga
Topics Stocks
Exposures US Equities
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Via Benzinga
US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.